Bora Pharmaceuticals Co., LTD. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 11, 2022
Share
Bora Pharmaceuticals Co., LTD. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was TWD 1,354.64 million compared to TWD 1,194.05 million a year ago. Net income was TWD 239.99 million compared to TWD 137.5 million a year ago. Basic earnings per share from continuing operations was TWD 2.4627 compared to TWD 1.4272 a year ago. Diluted earnings per share from continuing operations was TWD 2.4627 compared to TWD 1.4132 a year ago.
For the six months, sales was TWD 2,471.89 million compared to TWD 2,561.11 million a year ago. Net income was TWD 419.17 million compared to TWD 471.94 million a year ago. Basic earnings per share from continuing operations was TWD 4.2887 compared to TWD 4.8973 a year ago. Diluted earnings per share from continuing operations was TWD 4.2887 compared to TWD 4.8484 a year ago.
Bora Pharmaceuticals Co Ltd is a Taiwan-based company principally engaged in the agency and sales of western medicines, as well as the research, development, manufacture and sales of new drugs and health products. The Company's main products are categorized into prescription drugs and health care products, including central nervous drugs, cardiovascular drugs, antibiotics, antiviral agents, ophthalmic drugs, gastrointestinal drugs, foam ingots and health care products. In addition, the Company has biopharmaceutical technologies related to the development of cell lines for the production of protein drugs, the development and analysis of upstream and downstream processes, as well as the establishment of quality control and testing specifications and the creation of cell banks.
BORA PHARMACEUTICALS CO., LTD. 
